A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
SARS-CoV-2 Antibodies (IgG Nucleocapsid, IgM Spike), Qualitative : 31672
Test CodeCOVABS or 31672
Alias/See Also
Novel Coronavirus, COVID19, nCOV, Wuhan, Coronavirus
CPT Codes
86769x2
Includes
IgG Nucleocapsid and IgM Spike
Transport Container
Preferred Specimen
1 mL serum
Minimum Volume
1 mL
1 mL serum
Minimum Volume
1 mL
Transport Temperature
Refrigerated.
Specimen Stability
Room temperature: 4 days; Refrigerated: 7 days; Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, Grossly lipemic, Grossly icteric, Frozen Serum Separator Tube (SST®)
Methodology
Immunoassay (IA)
Setup Schedule
Monday - Saturday
Report Available
1-2 days (From receipt at performing laboratory)
Reference Range
See Laboratory Report
Clinical Significance
SARS-CoV-2 Antibodies (IgG Nucleocapsid, IgM Spike), Qualitative - Detection of IgG and IgM antibodies may indicate exposure to SARS-CoV-2 (COVID-19). IgM antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, with IgG antibodies typically reaching detectable levels simultaneously or 1-2 days later. Separate results will be provided for IgM and IgG. A positive antibody result may suggest an immune response to a primary infection with SARS-CoV-2, but the relationship between positivity and immunity to SARS-CoV-2 has not yet been firmly established. Antibody tests have not been shown to definitively diagnose or exclude SARS-CoV-2 infection. Diagnosis of COVID-19 is made by detection of SARS-CoV-2 RNA by molecular testing methods, consistent with a patient's clinical findings.
Performing Laboratory
Quest Diagnostics